Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nimbus
Biotech
How Takeda beat the rest of the industry to snag Nimbus' TYK2
Takeda's head of R&D Andy Plump is confident the company's TYK2 inhibitor will best Sotyktu on the market.
Max Bayer
Jan 11, 2024 10:30am
Nimbus tacks on $210M as investors swat away IRA concerns
Sep 6, 2023 7:00am
Takeda's $4B drug clears psoriasis in one-third of patients
Mar 20, 2023 8:15am
Takeda bets $4B upfront on Nimbus' phase 3-ready psoriasis drug
Dec 13, 2022 9:30am
Nimbus posts psoriasis data on rival to Bristol Myers' Sotyktu
Nov 30, 2022 6:00am
Frazier departs Merck after 30 years—Chutes & Ladders
Oct 28, 2022 9:30am
